GlassScriptPhysician profile
Halli J Elder
NPI 1720614704
$2,052.76
in general payments reported to CMS, 2019-2025
27 companies · $736 in 2025
The $736 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.87 · 2023: $757 · 2024: $494 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.23 | 2023-2025 | |
| Novo Nordisk INC | $271.51 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $210.50 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $203.40 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $122.00 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $96.90 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $94.86 | 2024-2025 | |
| Madrigal Pharmaceuticals | $76.77 | 2025 | Rezdiffra |
| Amgen INC. | $71.46 | 2023-2024 | Prolia, Evenity |
| Sanofi Pasteur INC. | $59.32 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.64 | 2023-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.75 | 2023-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $46.08 | 2023-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $41.01 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $39.95 | 2024-2025 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.08 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $28.20 | 2025 | Voquezna |
| Edwards Lifesciences Corporation | $27.27 | 2023 | |
| Corium, LLC | $22.96 | 2023 | Azstarys |
| Ultragenyx Pharmaceutical INC. | $22.35 | 2023 | |
| Merck Sharp & Dohme LLC | $21.74 | 2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Aimmune Therapeutics, INC. | $19.61 | 2025 | Zenpep |
| Hologic Sales and Service, LLC | $16.75 | 2023 | Thinprep 2000 Processor, Aptima |
| Xeris Pharmaceuticals, INC. | $16.53 | 2023 | Keveyis |
| Eisai INC. | $16.51 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $14.02 | 2023 | Seglentis, Livalo |
| Corcept Therapeutics | $13.36 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halli Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.